RuiPai Medical Secures Hundreds of Millions in Series C Funding to Advance Innovation and Build a Globally Leading Single-Use Endoscopy Platform

VCBeat (WeChat: vcbeat) has learned that Guangzhou Ruipai Medical Devices Co., Ltd. (hereinafter referred to as “REDPINE”) recently announced the completion of its Series C financing, with a total amounting to hundreds of millions of RMB. This round was led by Yuexiu Industrial Fund, with participation from SDAO Capital, Guoju Venture Capital, Caixin Private Equity, and others. The funds raised will be primarily used for capacity upgrades, product iteration and updates, and accelerating commercial expansion both domestically and overseas.

Founded in 2015, REDPINE is a national high-tech enterprise dedicated to the R&D, manufacturing, and sales of disposable endoscopes. Its product portfolio includes disposable endoscopes, medical endoscopic image processors, and disposable therapeutic instruments for endoscopic procedures. The REDPINE host platform is built on its independently developed IPS image processing system, integrating the SHIE ultra-high-definition imaging engine, IET image enhancement algorithms, spectral staining and EBI texture enhancement, as well as AI-assisted diagnostic methods such as AI-LD lesion recognition and detection. This significantly improves image detail resolution and clarity while providing physicians with accurate references for lesion assessment. Currently, the REDPINE host platform is compatible with endoscopes across all clinical departments, covering marketed products, products under development, and iterative versions, demonstrating strong scalability. The "one host, multiple scopes" configuration enables efficient sequential procedures, reduces costs, facilitates work for medical staff, and benefits patients.

In 2022, REDPINE’s medical products reached more than 1,000 hospitals, with a market share exceeding 50% in key regions. Among its initiatives, REDPINE organized several national academic forums under the theme “Innovations in Urology: Jingrui Forum” across multiple provinces and municipalities, attracting nearly 2,000 participants. While consolidating its presence in the mid-to-high-end medical market, REDPINE collaborated with leading domestic experts to conduct hands-on training programs at primary care hospitals, helping enhance their diagnostic and treatment capabilities and facilitating better access to healthcare for local communities.

Amidst the process of globalization, REDPINE has maintained a style that emphasizes both enterprising innovation and steady execution. In 2022, REDPINE made successive appearances at Digestive Disease Week (DDW 2022), the American Urological Association Annual Meeting (AUA 2022), the European Association of Urology Congress (EAU 2022), the Arab Association of Urology & Jordanian Association of Urological Surgeons Annual Meeting (AAU&JAUS 2022), and the 11th Emirates Urology Society Conference (EUSC). To date, REDPINE has obtained 16 overseas registration certificates, including CE certification, with its overseas sales channels covering more than 20 countries and regions across Europe, the Middle East, North America, South America, and Southeast Asia.

Leveraging its keen insights into clinical needs and a product portfolio closely aligned with clinical practice, REDPINE has rapidly captured the domestic market for single-use endoscopes. The company’s deep industry expertise, combined with synergies in more efficient production and regulatory approval resources, underpins its sustained commercial competitiveness. In recent years, driven by the significant commercial potential unlocked by the advantages of single-use endoscopes—such as specialized application, low cost, and disposability—REDPINE is accelerating its transformation into a globally leading single-use endoscopy platform, enabling patients worldwide to access affordable, high-quality medical resources made in China.